An investor sold two Mutant Apes NFTs for 1 Ether (ETH) each after holding them for three years. The original listed purchase prices were 6.13 ETH and 7.5 ETH, totaling 13.63 ETH. Selling them for 2 ETH combined implies an 11.63 ETH loss, or about 85% of the original cost. This significant loss highlights the volatility and risks in NFT investments, especially over long holding periods.
Regarding the sale of two Mutant Apes NFTs, here is Pluang's market snapshot as of Oct 24, 2026 00:22 WIB: Among 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell today. Notable movers include LUNC (Terra Classic) at Rp0,838 with a 3.29% increase and a Pluang order activity of 24% Sell / 76% Buy, ATOM (Cosmos) at Rp31.747 with a 3.25% rise, and UNI (Uniswap) at Rp129.242 with a 3.05% gain. The most notable figure is LUNC's 76% Buy order activity on Pluang.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
